Q1 2024 Qualitative Update

Performance In Line with Expectations for Full-Year 2024

Lonza Group AG / Key word(s): Quarter Results Q1 2024 Qualitative Update: Performance In Line with Expectations for Full-Year 2024 14-May-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR

• Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
• Softer performance in Q1 2024, normalizing across H1 2024
• Sustained commercial demand in CDMO business with initial signs of early-stage recovery
• Key growth projects due to start in 2024 progressing in line with plan 
• Revised definition of three Alternative Performance Measures from H1 2024

Basel, Switzerland, 14 May 2024 – In its quarterly qualitative update, Lonza reported a softer Q1, with performance across H1 expected to align with the Full-Year 2024 trajectory. 

Lonza confirms its Outlook 2024 at flat sales growth in CER and Core EBITDA margin of high 20s. H2 2024 sales are expected to be solid, reflecting the timing of batch releases. 

In Biologics, there was good momentum across the division with sustained commercial demand, while clinical demand remained softer, despite early signs of biotech funding recovery. The Small Molecules division also saw strong commercial demand, and made continued progress on strategic investments. Cell & Gene delivered improved commercial and operational performance in Cell & Gene Technology, while market headwinds impacted Bioscience primarily in its media business. Finally, the performance of the Capsules & Health Ingredients division was softer than expected due to a combination of weaker demand for pharma hard capsules in western markets, and lower margins in its nutraceutical business despite improved demand.